Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Tesamorelin Acetate
Also known as: Egrifta, Egrifta SV
Confidence
Updated 2026-03-18
Tesamorelin is a synthetic GHRH analog that is the only FDA-approved peptide therapy specifically for the reduction of excess abdominal fat. Originally approved for HIV-associated lipodystrophy, it has gained significant attention in the anti-aging and metabolic optimization space as a legal, well-characterized GH secretagogue.
Class
GHRH Analog
Routes
Subcutaneous
Half-Life
26 minutes (terminal half-life: 38 minutes)
Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone. This leads to increased IGF-1 levels, enhanced lipolysis (particularly visceral fat), and improved body composition without directly suppressing the hypothalamic-pituitary-GH axis.
Half-Life
26 minutes (terminal half-life: 38 minutes)
Bioavailability
Subcutaneous: ~4%
FDA-approved: reduction of excess abdominal fat in HIV-associated lipodystrophy. Off-label: visceral fat reduction, GH optimization, metabolic improvement, cognitive support.
Phase III trials demonstrated significant reduction in trunk fat (-15.2% vs placebo), increased IGF-1 levels, and improved lipid profiles in HIV patients. Limited controlled data for off-label indications. Favorable safety profile established across multiple trials.
Human Studies
25
Animal Studies
40
Common: injection site reactions (erythema, pruritus), arthralgia, peripheral edema. Rare: hypersensitivity reactions, fluid retention. Contraindicated in active malignancy, disruption of hypothalamic-pituitary axis, pregnancy.
FDA-approved with specific indication. Can be prescribed off-label by licensed providers. Also available through compounding under 503A.
Drug Interactions: May affect glucose metabolism — monitor in diabetic patients. Monitoring: IGF-1, fasting glucose, HbA1c. Research Gaps: Long-term data in non-HIV populations limited. Effects on NAFLD/NASH under investigation.
Subcutaneous
Common Range
2 mg/day
Timing
Morning, fasted
Frequency
Daily
Cycling
Continuous use per FDA label; some providers use 3–6 month cycles
Reconstitution
Provided as lyophilized powder with diluent
Storage
Refrigerated; use within 14 days of reconstitution
Important Note
FDA-approved dose is 2mg daily. Rotate injection sites on abdomen.
Connect with a verified provider offering Tesamorelin therapy near you.
GHRH Analog
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid GHRH sequence. Originally FDA-approved for diagnostic use in assessing growth hormone secretion, it has become a cornerstone of legitimate peptide therapy for growth hormone optimization due to its established safety profile and compounding eligibility.
GH Secretagogue
CJC-1295 is a synthetic analog of GHRH(1-29) with modifications to extend its half-life. Available in two forms: with Drug Affinity Complex (DAC) for prolonged action, and without DAC (also called Modified GRF 1-29) for shorter, more pulsatile action. Frequently combined with ipamorelin for synergistic GH release.
GH Secretagogue
Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to stimulate GH release from the pituitary. It is considered one of the most selective GH secretagogues, with minimal effect on cortisol, prolactin, and other hormones — making it a preferred choice in combination protocols with CJC-1295.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.